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ABSTRACT
Objectives This study evaluated the comparative 
effectiveness of vitamin K antagonists (VKAs), direct 
thrombin inhibitors (DTIs) and factor Xa inhibitors (FXaI) 
in patients with atrial fibrillation (AF) at risk of stroke in 
everyday practice.
Methods Data from patients with AF and Congestive heart 
failure, Hypertension, Age 75 years, Diabetes mellitus, prior 
Stroke, TIA, or thromboembolism, Vascular disease, Age 65-74 
years, Sex category (CHA2DS2- VASc) score ≥2 (excluding 
gender) in the Global Anticoagulant Registry in the FIELD–
Atrial Fibrillation registry were analysed using an improved 
method of propensity weighting, overlap weights and Cox 
proportional hazards models.
Results All- cause mortality, non- haemorrhagic stroke/
systemic embolism (SE) and major bleeding over 2 years were 
compared in 25 551 patients, 7162 (28.0%) not treated 
with oral anticoagulant (OAC) and 18 389 (72.0%) treated 
with OAC (FXaI (41.8%), DTI (11.4%) and VKA (46.8%)). 
OAC treatment compared with no OAC treatment was 
associated with decreased risk of all- cause mortality (HR 0.82 
(95% CI 0.74 to 0.91)) and non- haemorrhagic stroke/SE 
(HR 0.71 (95% CI 0.57 to 0.88)) but increased risk of major 
bleeding (HR 1.46 (95% CI 1.15 to 1.86)). Non- vitamin K 
antagonist oral anticoagulant (NOAC) use compared with no 
OAC treatment was associated with lower risks of all- cause 
mortality and non- haemorrhagic stroke/SE (HR 0.67 (95% CI 
0.59 to 0.77)) and 0.65 (95% CI 0.50 to 0.86)) respectively, 
with no increase in major bleeding (HR 1.10 (95% CI 0.82 
to 1.47)). NOAC use compared with VKA use was associated 
with lower risk of all- cause mortality and major bleeding 
(rates/100 patient- years 3.6 (95% CI 3.3 to 3.9) vs 4.8 (95% 
CI 4.5 to 5.2) and 1.0 (95% CI 0.9 to 1.1) vs 1.4 (95% CI 
1.2 to 1.6); HR 0.79 (95% CI 0.70 to 0.89) and 0.77 (95% 
CI 0.61 to 0.98) respectively), with similar risk of non- 
haemorrhagic stroke/SE (rates/100 patient- years 0.8 (95% CI 
0.7 to 0.9) versus 1.0 (95% CI 0.8 to 1.1); HR 0.96 (95% CI 
0.73 to 1.25).
Conclusion Important benefits in terms of mortality 
and major bleeding were observed with NOAC versus 
VKA with no difference among NOAC subtypes.
Trial registration number NCT01090362.
INTRODUCTION
Oral anticoagulation is recommended in patients 
with atrial fibrillation (AF) at moderate to high risk 
of stroke.1 2 Oral anticoagulants (OACs) comprise 
vitamin K antagonists (VKAs, eg, warfarin) and the 
newer non- vitamin K antagonist oral anticoagu-
lants (NOACs), direct thrombin inhibitors (DTIs) 
and factor Xa inhibitors (FXaI).1 2 Anticoagu-
lants reduced ischaemic stroke risk in randomised 
controlled trials (RCTs), but their use is associated 
with increased risk of bleeding, ranging from minor 
bleeding to fatal intracranial or extracranial haem-
orrhage.1–3 In RCTs comparing NOACs and VKAs, 
NOACs have shown superiority or non- inferiority 
with regard to the reduction of stroke or systemic 
embolus and better safety, with less intracranial 
haemorrhage.4–8 Although such trials are the gold 
standard for demonstrating the efficacy of a partic-
ular therapy, they are limited to patients who meet 
restrictive inclusion and exclusion criteria and in 
particular the exclusion of individuals with multiple 
comorbidities or perceived bleeding risks. Such trial 
patients inevitably do not reflect the full spectrum 
of patients managed in clinical practice. Evidence 
from suitably designed observational studies can 
complement findings from RCTs and provide infor-
mation about outcomes in everyday practice.9
We aimed to examine the comparative effective-
ness of VKAs, DTI and FXaI initiating treatment 
on 2- year outcomes in terms of mortality, stroke/
systemic embolism (SE) and major bleeding in 
patients with newly diagnosed AF with an indica-
tion for oral anticoagulation included in The Global 
Anticoagulant Registry in the FIELD–Atrial Fibrilla-
tion (GARFIELD- AF).10 For this purpose, we used 
a newly developed method, overlap propensity 
weighting, which avoids excluding patients (as with 
matching improved) and gives the most weight to 
propensities where there is equipoise (see further).11
METHODS
Study design and participants
The GARFIELD- AF is a prospective, multinational, 
observational study of adults with recently diag-
nosed non- valvular AF and at least one risk factor 
for stroke.10 GARFIELD- AF registry recruited 
patients from a range of representative care settings 
in each participating country.10 12 Investigator sites 
were selected randomly (apart from 18 sites, out 
of >1000), in order to be representative of the 
different care settings in each participating country 
(office- based practice; hospital departments 
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including neurology, cardiology, geriatrics, internal medicine 
and emergency; anticoagulation clinics; and general or family 
practice). No specific treatments, tests or procedures were 
mandated by the study protocol. Treatment decisions (including 
no anticoagulation and no antithrombotic therapy) were solely 
at the discretion of treating physicians. Recruitment took place 
in five independent sequential cohorts from 35 countries (online 
supplemental table S1).10 Cohorts 3–5, prospectively recruited 
Table 1 Baseline characteristics by treatment at baseline
Baseline characteristics
Patients treated with OAC









  Male 4084 (53.1) 1151 (55.1) 4501 (52.3) 3846 (53.7)
  Female 3610 (46.9) 939 (44.9) 4104 (47.7) 3316 (46.3)
Age, median (Q1; Q3), years 75.0 (69.0; 81.0) 72.0 (66.0; 78.0) 73.0 (67.0; 79.0) 73.0 (66.0; 80.0)
Age, n (%), years
  <65 894 (11.6) 375 (17.9) 1468 (17.1) 1423 (19.9)
  65–69 1322 (17.2) 454 (21.7) 1578 (18.3) 1223 (17.1)
  70–74 1557 (20.2) 414 (19.8) 1708 (19.8) 1276 (17.8)
  ≥75 3921 (51.0) 847 (40.5) 3851 (44.8) 3240 (45.2)
Ethnicity, n (%)
  Caucasian 4876 (65.2) 1411 (68.7) 5954 (70.5) 3829 (54.5)
  Hispanic/Latino 351 (4.7) 91 (4.4) 733 (8.7) 473 (6.7)
  Asian 2089 (27.9) 510 (24.8) 1590 (18.8) 2602 (37.1)
  Afro- Caribbean/mixed/other 164 (2.2) 42 (2.0) 166 (2.0) 118 (1.7)
Type of atrial fibrillation, n (%)
  Permanent 1026 (13.3) 184 (8.8) 1540 (17.9) 791 (11.0)
  Persistent 1222 (15.9) 383 (18.3) 1325 (15.4) 698 (9.7)
  Paroxysmal 2530 (32.9) 612 (29.3) 1784 (20.7) 2074 (29.0)
  New onset (unclassified) 2916 (37.9) 911 (43.6) 3956 (46.0) 3599 (50.3)
Medical history, n (%)
  Heart failure 1840 (23.9) 566 (27.1) 2220 (25.8) 2110 (29.5)
  Acute coronary syndromes 890 (11.6) 227 (10.9) 1171 (13.7) 1282 (18.1)
  Vascular disease* 1933 (25.1) 590 (28.2) 2562 (29.8) 2818 (39.3)
  Carotid occlusive disease 281 (3.7) 81 (3.9) 297 (3.5) 231 (3.3)
  Venous thromboembolism 194 (2.5) 33 (1.6) 235 (2.7) 123 (1.7)
  Prior stroke/TIA/SE 1030 (13.4) 266 (12.7) 1170 (13.6) 819 (11.4)
  Prior bleeding 168 (2.2) 34 (1.6) 146 (1.7) 343 (4.8)
  Hypertension 6291 (81.8) 1763 (84.4) 7299 (84.9) 5774 (80.7)
  Hypercholesterolaemia 3449 (46.2) 1023 (50.3) 3927 (47.8) 2841 (42.0)
  Diabetes 1969 (25.6) 569 (27.2) 2563 (29.8) 1882 (26.3)
  Cirrhosis 26 (0.3) 6 (0.3) 49 (0.6) 55 (0.8)
  Moderate to severe CKD 904 (12.2) 205 (10.1) 1202 (14.7) 849 (12.7)
  Dementia 166 (2.2) 32 (1.5) 93 (1.1) 156 (2.2)
FXaI inhibitors medication, n (%)
  Rivaroxaban 3845 (50.0) – – –
  Apixaban 2945 (38.3) – – –
  Edoxaban 270 (3.5) – – –
  Other/unknown 634 (8.2) – – –
AP treatment, n (%) 1416 (18.4) 369 (17.7) 2176 (25.3) 4626 (64.6)
CHA2DS2- VASc score, median (Q1; Q3) 4.0 (3.0; 4.0) 4.0 (3.0; 4.0) 4.0 (3.0; 5.0) 4.0 (3.0; 5.0)
HAS- BLED score,† median (Q1; Q3) 1.0 (1.0; 2.0) 1.0 (1.0; 2.0) 1.0 (1.0; 2.0) 2.0 (1.0; 2.0)
GARFIELD- AF death score,‡ median (Q1; Q3) 4.8 (3.0; 8.2) 4.4 (2.6; 7.1) 5.9 (3.7; 9.8) 6.9 (4.0; 12.1)
GARFIELD- AF stroke score,§ median (Q1; Q3) 1.4 (1.1; 2.0) 1.3 (1.0; 1.8) 1.7 (1.3; 2.4) 2.4 (1.8; 3.5)
GARFIELD- AF bleeding score,¶ median (Q1; Q3) 1.7 (1.2; 2.3) 1.5 (1.1; 2.1) 2.3 (1.7; 3.2) 1.4 (1.0; 2.1)
*Defined as peripheral artery disease and/or coronary artery disease.
†The risk factor ‘Labile INRs’ is not included in the HAS- BLED score as it is not collected at baseline. As a result, the maximum HAS- BLED score at baseline is 8 points (not 9).
‡Estimated probability of dying within two years of follow- up.
§Estimated probability of developing a non- haemorrhagic stroke/SE within two years of follow- up.
¶Estimated probability of developing a major bleeding within two years of follow- up.
AP, antiplatelet; CKD, chronic kidney disease; FXaI, factor Xa inhibitors; GARFIELD- AF, Global Anticoagulant Registry in the FIELD–Atrial Fibrillation; OAC, oral anticoagulant; SE, 
systemic embolism; TIA, transient ischaemic attack.
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during April 2013–August 2016, were included in this anal-
ysis (NOACs had not yet been introduced into many countries 
during the recruitment period for cohorts 1 (2010–2011) and 2 
(2011–2013)).
Men and women aged ≥18 years with non- valvular AF 
diagnosed according to standard local procedures within the 
previous 6 weeks, and with at least one additional risk factor 
for stroke as judged by the investigator, were eligible for inclu-
sion in GARFIELD- AF; patients with a transient reversible cause 
of AF and those for whom follow- up was not envisaged or 
possible were excluded.10 Only patients with a clear indication 
for anticoagulation (CHA2DS2- VASc score ≥2 for males and 
CHA2DS2- VASc score ≥3 for females) were included in this 
analysis.
Ethics statement
Independent ethics committee and hospital- based institutional 
review board approvals were obtained, as necessary, for the 
registry protocol. Additional approvals were obtained from 
individual study sites. GARFIELD- AF is conducted in accor-
dance with the principles of the Declaration of Helsinki, local 
Table 2 Event rates (per 100 person- years) within 2- year follow- up by treatment at baseline
Treatment at baseline
Outcome
All- cause mortality Non- haemorrhagic stroke/SE Major bleeding
Events Rate (95% CI) Events Rate (95% CI) Events Rate (95% CI)
FXaI 536 3.7 (3.4 to 4.0) 112 0.8 (0.6 to 0.9) 152 1.0 (0.9 to 1.2)
DTI 130 3.3 (2.8 to 3.9) 34 0.9 (0.6 to 1.2) 29 0.7 (0.5 to 1.1)
Any NOAC 666 3.6 (3.3 to 3.9) 146 0.8 (0.7 to 0.9) 181 1.0 (0.9 to 1.1)
VKA 773 4.8 (4.5 to 5.2) 153 1.0 (0.8 to 1.1) 223 1.4 (1.2 to 1.6)
Any OAC 1439 4.1 (3.9 to 4.4) 299 0.9 (0.8 to 1.0) 404 1.2 (1.1 to 1.3)
No OAC 737 5.6 (5.2 to 6.0) 168 1.3 (1.1 to 1.5) 102 0.8 (0.6 to 1.0)
DTI, direct thrombin inhibitor; FXaI, factor Xa inhibitor; NOAC, non- vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; SE, systemic embolism; VKA, vitamin K 
antagonist.
Figure 1 Adjusted* cumulative (A) mortality (B) non- haemorrhagic stroke/SE and (C) major bleeding incidence curves and HR of OAC treatment 
(ref.: no OAC treatment) at baseline. Solid lines represent the point estimate, and dashed lines represent the 95% CIs. *Obtained using an overlap- 
weighted Cox model. Variables included in the weighting scheme are: country and cohort enrolment, sex, age, ethnicity, type of AF, care setting 
speciality and location, congestive heart failure, acute coronary syndromes, vascular disease, carotid occlusive disease, prior stroke/TIA/SE, prior 
bleeding, venous thromboembolism, hypertension, hypercholesterolaemia, diabetes, cirrhosis, moderate to severe CKD, dementia, hyperthyroidism, 
hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, systolic and diastolic blood pressure at diagnosis and baseline 
antiplatelet use. AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; OAC, oral anticoagulants; SE: Systemic embolism; TIA, 
transient ischaemic attack.
 on F
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regulatory requirements and the International Conference on 
Harmonisation Good Pharmacoepidemiological and Clinical 
Practice Guidelines. Written informed consent was obtained 
from all study participants.
Data collection and quality control
GARFIELD- AF data were captured using an electronic case 
report form (eCRF).10 Oversight of operations and data manage-
ment were performed by the coordinating centre, the Throm-
bosis Research Institute (TRI; London, UK), with support from 
Quintiles (Durham, North Carolina, USA), The University of 
Birmingham Department of Primary Care Clinical Sciences 
(Birmingham, UK), Thrombosis Research Group–Brigham and 
Women’s Hospital (Boston, Massachusetts, USA) and AIXIAL 
(Paris, France). Submitted data were examined for complete-
ness and accuracy by the coordinating centre, the TRI, and data 
queries were sent to study sites. The GARFIELD- AF protocol 
requires that 20% of all eCRFs are monitored against source 
documentation, that there is an electronic audit trail for all data 
modifications and that critical variables are subjected to addi-
tional audit.10 13
Baseline characteristics collected at study entry included: 
medical history, care setting, type of AF, date and method of 
diagnosis of AF, symptoms, antithrombotic treatment (VKAs, 
NOACs and antiplatelet (AP)), as well as all cardiovascular 
drugs. Race was classified by the investigator in agreement with 
the patient. Vascular disease included coronary artery disease 
and/or peripheral artery disease. Chronic kidney disease was 
Figure 2 Unadjusted and adjusted* HRs and corresponding 95% CIs for selected outcomes at 2 years of follow- up by treatment at baseline. 
*Obtained using an overlap- weighted Cox model. Variables included in the weighting scheme are: country and cohort enrolment, sex, age, ethnicity, 
type of AF, care setting speciality and location, congestive heart failure, acute coronary syndromes, vascular disease, carotid occlusive disease, prior 
stroke/TIA/SE, prior bleeding, venous thromboembolism, hypertension, hypercholesterolaemia, diabetes, cirrhosis, moderate to severe CKD, dementia, 
hyperthyroidism, hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, systolic and diastolic blood pressure at diagnosis and 
baseline antiplatelet use. AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; NOAC, non- vitamin K oral antagonist; OAC, oral 
anticoagulants; SE, systemic embolism; TIA, transient ischaemic attack; VKA, vitamin K antagonists.
Figure 3 Unadjusted and adjusted* HRs and corresponding 95% CIs for selected outcomes at 2 years of follow- up by treatment at baseline. 
*Obtained using an overlap- weighted Cox model. Variables included in the weighting scheme are: country and cohort enrolment, sex, age, ethnicity, 
type of AF, care setting speciality and location, congestive heart failure, acute coronary syndromes, vascular disease, carotid occlusive disease, prior 
stroke/TIA/SE, prior bleeding, venous thromboembolism, hypertension, hypercholesterolaemia, diabetes, cirrhosis, moderate to severe CKD, dementia, 
hyperthyroidism, hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, systolic and diastolic blood pressure at diagnosis and 
baseline antiplatelet use. AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; NOAC, non- vitamin K oral antagonist; OAC, oral 
anticoagulants; SE, systemic embolism; TIA, transient ischaemic attack; VKA, vitamin K antagonists.
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classified according to National Kidney Foundation guide-
lines into moderate to severe (stages 3–5), mild (stages 1 and 
2) or none. Cerebrovascular events defined as stroke included 
primary ischaemic stroke, primary intracerebral haemorrhage 
and secondary haemorrhagic ischaemic stroke. Acute coronary 
syndrome (ACS) included unstable angina, ST- elevation myocar-
dial infarction (STEMI) and non- STEMI. Non- haemorrhagic 
stroke/SE includes either ischaemic stroke or unknown type of 
stroke. Major bleeding was defined as clinically overt bleeding 
associated with fall in haemoglobin of ≥2 g/dL, or associated 
with transfusion of packed red blood cells or whole blood, or 
bleeding in a critical site, namely intracranial (spontaneous 
intracerebral, intraventricular, subarachnoidal, subdural and 
epidural), intraspinal, pericardial, intra- articular, intramuscular 
with compartment syndrome, or retroperitoneal, or leading to 
a fatal outcome.10
Data on components of the CHA2DS2- VASc, Hypertension 
(uncontrolled systolic blood pressure >160 mm Hg), Abnormal 
renal or liver function, previous Stroke, Bleeding history or 
predisposition, Labile international normalized ratios, Elderly, 
and concomitant Drugs or alcohol excess (HAS- BLED) and 
GARFIELD- AF risk stratification schemes were collected and 
calculated retrospectively.14–16 HAS- BLED scores were calcu-
lated excluding fluctuations in international normalised ratio. 
Collection of follow- up data occurred at 4- month intervals up to 
24 months. Data for this report were extracted from the study 
database on 19 November 2018.
Statistical analysis
Clinical endpoints of the study were all- cause mortality, stroke/
SE and major bleeding manifest over 2- year follow- up. Contin-
uous baseline variables are expressed as median (IQR) and cate-
gorical variables as frequency and percentage. Occurrence of 
clinical outcomes is described using the number of events, event 
rate per 100 person- years and 95% CI. Person- year rates were 
estimated using a Poisson model, with the number of events as 
the dependent variable and the log of time as an offset (ie, a 
covariate with a known coefficient of 1). Only the first occur-
rence of each event was considered.
The Risk Of Bias In Non- randomised Studies – of Interven-
tions (ROBINS- I) tool was used to ensure causal statements are 
Figure 4 Adjusted* cumulative (A) mortality, (B) non- haemorrhagic stroke/SE and (C) major bleeding incidence curves and HR of NOAC treatment 
(ref.: VKA treatment) among OAC- treated patients at baseline. Solid lines represent the point estimate, and dashed lines represent the 95% CIs. 
*Obtained using an overlap- weighted Cox model. Variables included in the weighting scheme are: country and cohort enrolment, sex, age, ethnicity, 
type of AF, care setting speciality and location, congestive heart failure, acute coronary syndromes, vascular disease, carotid occlusive disease, prior 
stroke/TIA/SE, prior bleeding, venous thromboembolism, hypertension, hypercholesterolaemia, diabetes, cirrhosis, moderate to severe CKD, dementia, 
hyperthyroidism, hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, systolic and diastolic blood pressure at diagnosis and 
baseline antiplatelet use. AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; NOAC, non- vitamin K oral antagonist; SE: systemic 
embolism; TIA, transient ischaemic attack. VKA, vitamin K antagonists.
 on F
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valid.17 18 Cumulative mortality, stroke/SE and major bleeding 
incidence and HRs for OAC versus no OAC, NOAC versus VKA, 
NOAC versus no OAC and VKA versus no OAC were obtained 
using a Cox proportional hazards model using a propensity 
method of overlap weighting to balance covariates in the popu-
lation.11 This applied method overlaps weights and optimises the 
efficiency of comparisons by defining the population with the 
most overlap in the covariates between treatment groups. This 
scheme eliminates the potential for outlier weights by avoiding 
a weight based on a ratio calculation using values bounded by 0 
and 1. Thus, when using overlap weights, many of the concerns 
regarding the assessment and the trimming of the weights are 
eliminated (online supplemental figure S1 and S2). The compar-
ison of DTI versus FXaI versus VKA is performed using a new 
method of generalised overlap weights for multiple treatments.19 
Covariates evaluated in the weighting scheme included demo-
graphic characteristics, medical history and other characteristics 
(online supplemental figure S3 and S4). Treatment was defined 
as the first treatment received at the time of enrolment, approxi-
mating ‘intention- to- treat’. Patients with missing values were not 
removed from the study; single imputation was applied for the 
comparative effectiveness analysis. As a sensitivity analysis, all 
models were run on the five imputed datasets. The differences in 
model results were negligible so single imputation was retained. 
Data analysis was carried out at the TRI using SAS V.9.4 (SAS 
Institute Inc, Cary, North Carolina, USA).
RESULTS
Study population
A total of 34 926 patients were enrolled in GARFIELD- AF 
cohorts 3, 4 and 5. After exclusion of patients with CHA2DS2- 
VASc score <2 (excluding gender), patients treated with 
VKAs before enrolment, and patients with missing treatment 
or follow- up information, the remaining study population 
comprised 25 551 patients, 7162 (28.0%) not treated with OACs 
and 18 389 (72.0%) patients treated with OACs (FXaI 7694 
(41.8%), DTI 2090 (11.4%) and VKA 8605 (46.8%) (online 
supplemental figure S5). Baseline characteristics by treatment 
at baseline are shown in table 1 and online supplemental table 
S2 . Although most baseline characteristics were similar across 
groups, some features differed between OAC groups and the no 
OAC group. In the OAC groups, patients were more likely to 
be Caucasian and less likely to be Asian than in the no OAC 
group. The prevalence of paroxysmal AF was lower in the VKA 
subgroup, and the prevalence of unclassified (at baseline) AF was 
lower in the FXaI subgroup. The no OAC group had a higher 
proportion of patients with congestive heart failure, coronary 
artery disease, acute coronary syndrome, vascular disease and 
prior bleeding history than the OAC groups; they were also at 
higher risk of death and stroke/SE according to GARFIELD- AF 
risk score. Median HAS- BLED score was higher in the no OAC 
group compared with other groups (2.0 vs 1.0, respectively). 
The median (Q1; Q3) time in therapeutic range (TTR) among 
VKA- treated patients was 62% (41%; 77%).
Clinical outcomes
The rates per hundred patient- years of all cause death and of 
non- haemorrhagic stroke/SE were substantially lower and the 
risk of major bleeding substantially higher with OAC versus no 
OAC, 4.1 (95% CI 3.9 to 4.4) versus 5.6 (95% CI 5.2 to 6.0), 
0.9 (95% CI 0.8 to 1.0) versus 1.3 (95% CI 1.1 to 1.5) and 1.2 
(95% CI 1.1 to 1.3) versus 0.8 (95% CI 0.6 to 1.0) respectively. 
The rates per 100 patient- years of all cause death and of major 
bleeding were significantly lower with NOAC than with VKA, 
Figure 5 Adjusted* HRs and corresponding 95% CIs for selected outcomes at 2 years of follow- up by OAC treatment at baseline. The reference 
considered is the treatment reported as second. *Obtained using an overlap- weighted Cox model. Variables included in the weighting scheme are: 
country and cohort enrolment, sex, age, ethnicity, type of AF, care setting speciality and location, congestive heart failure, acute coronary syndromes, 
vascular disease, carotid occlusive disease, prior stroke/TIA/SE, prior bleeding, venous thromboembolism, hypertension, hypercholesterolaemia, 
diabetes, cirrhosis, moderate to severe CKD, dementia, hyperthyroidism, hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, 
systolic and diastolic blood pressure at diagnosis and baseline antiplatelet use. OAC, oral anticoagulants; DTI, direct thrombin inhibitor; FXaI, factor Xa 
inhibitors; VKA, vitamin K antagonists; NOAC, non- vitamin K oral antagonist; SE, systemic embolism; TIA, transient ischaemic attack.
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3.6 (95% CI 3.3 to 3.9) versus 4.8 (95% CI 4.5 to 5.2) and 1.0 
(95% CI 0.9 to 1.1) versus 1.4 (95% CI 1.2 to 1.6) respectively, 
whereas the rate of non- haemorrhagic stroke/SE was similar and 
0.8 (95% CI 0.7 to 0.9) versus 1.0 (95% CI 0.8 to 1.1) (table 2).
OACs use compared with no OAC treatment was associated 
with a significant reduction in all- cause mortality and non- 
haemorrhagic stroke/SE risk (HR 0.82 (95% CI 0.74 to 0.91) 
and 0.71 (95% CI 0.57 to 0.88)), respectively, and with a signif-
icant increase in the risk of major bleeding (HR 1.46 (95% CI 
1.15 to 1.86)) (figures 1 and 2, (online supplemental table S3) in 
adjusted analyses. NOACs use compared with no OAC treatment 
was associated with a significant reduction in all- cause mortality 
and non- haemorrhagic stroke/SE risk (HR 0.67 (95% CI 0.59 
to 0.77)) and 0.65 (95% CI 0.50 to 0.86)), respectively, with no 
significant increase in the risk of major bleeding 1.10 (95% CI 
0.82 to 1.47) (figure 3, online supplemental table S4). VKA use 
compared with no OAC treatment was associated with a signif-
icant reduction in non- haemorrhagic stroke/SE risk (HR 0.75 
(95% CI 0.58 to 0.98)), a significant increase in major bleeding 
risk (HR 1.86 (95% CI 1.42 to 2.44)), and no significant differ-
ence in all- cause mortality and 0.93 (95% CI 0.82 to 1.04) 
(figure 3, online supplemental table S4). NOAC use compared 
with VKA use was associated with a significantly lower risk of 
all- cause mortality and of major bleeding (HR 0.79 (95% CI 
0.70 to 0.89) and 0.77 (95% CI 0.61 to 0.98), respectively), 
but with similar risk of non- haemorrhagic stroke/SE (HR 0.96 
(95% CI 0.73 to 1.25)) (figures 2 and 4, (online supplemental 
table S3).
The individual comparisons of DTI, FXaI and VKA are presented 
in online supplemental table S5, figure 5 and online supplemental 
figure S6. Use of both DTI and FXaI compared with VKA use is 
associated with a lower risk of all- cause mortality (HR 0.83 (95% CI 
0.71 to 0.98) and 0.77 (95% CI 0.65 to 0.92)), respectively, with no 
difference between DTI and FXaI. There is no difference in the risk 
of stroke/SE between DTI, FXaI and VKA. Use of DTI compared 
with use of VKA is associated with a significantly lower risk of major 
bleeding (HR 0.68 (95% CI 0.47 to 0.98)), whereas the decrease 
in bleeding risk is non- significant with of FXaI (HR 0.84 (95% CI 
0.63 to 1.12)). FXaI is associated with a non- significant higher risk 
of major bleeding compared with DTI (HR 1.24 (95% CI 0.90 to 
1.73)).
DISCUSSION
In a broad clinical population of patients with new- onset AF, 
our study confirms that in patients with AF, OAC treatment 
is associated with a significantly lower risk of death and non- 
haemorrhagic stroke/SE compared with no OAC treatment at 
the cost of a significant increase in the risk of bleeding.3 The 
most frequent reasons of no OAC in patients with a high risk of 
stroke was high bleeding risk/previous bleeding events followed 
by physician choice and patient refusal to take OAC. The risk 
reduction for death in our study is of lesser magnitude than that 
reported in previous meta- analysis.3 This difference probably 
reflects differences between observational versus randomised 
trials; unidentified or unavailable factors for adjustment may 
have influenced treatment decisions and outcomes. Poor inter-
national normalised ratio (INR) control under VKA treatment 
may also be involved; in an analysis of GARFIELD- AF data, a 
large proportion of patients with AF treated with VKAs had poor 
control (TTR <65%), which was associated with 2.4- fold higher 
risk of death.20
However, NOAC use compared with no treatment brings 
important information as it is associated with a significant risk 
reduction for both death and non- haemorrhagic stroke/SE, 
without significant increase in the risk of bleeding, contrary to 
VKA use where a significant risk reduction for non- haemorrhagic 
stroke/SE was observed with no reduction in the risk of death 
and with a significant increase in bleeding. In Apixaban Versus 
Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrilla-
tion Patients Who Have Failed or Are Unsuitable for Vitamin 
K Antagonist Treatment (AVERROES) trial, patients thought to 
be non- amenable to VKA were randomised to aspirin or apix-
aban. A significant risk reduction for stroke/SE without increase 
in the risk of major bleeding and intracranial haemorrhage was 
observed in patients who received apixaban versus aspirin.21 Our 
observations carry an important message as they derive from 
an unselected real- world registry population followed up for 2 
years with robust methods and quality control.13 These results 
should encourage the prescription of NOAC in patients where 
perceived moderate bleeding risks inhibit the use of anticoagula-
tion despite elevated stroke risks.
The individual comparisons of DTI, FXaI and VKA are consistent, 
in this non- trial population, with the advantages of NOACs over 
VKAs in terms of clinical outcomes in patients with AF, as demon-
strated in pivotal trials, systematic reviews and meta- analyses. In our 
study, the results achieved with DTI and FXaI in comparison with 
VKAs are consistent across NOAC subtypes. Both classes are asso-
ciated with a significant reduction in the risk of all- cause mortality. 
However, compared with VKA, the risk of stroke/SE is not signifi-
cantly different. There is no difference in bleeding risk between DTI 
and FXaI, but compared with VKA, the DTI is associated with a 
significant reduction in major bleeding, while the risk reduction 
achieved with the FXaIs was not significant.
Our results are consistent with findings from another AF 
registry, the Outcomes Registry for Better Informed Treatment 
of Atrial Fibrillation II registry, in which rates of major bleeding 
over 1- year follow- up in patients with newly diagnosed AF or 
recent initiation of a NOAC were similar among NOAC- treated 
and VKA- treated patients. However, that analysis did not 
involve multivariate adjustment, such that baseline differences 
in bleeding risk between patients on NOACs and VKAs were not 
taken into account.22 Our results are also broadly consistent with 
a Swedish population- based study of 22 198 OAC- naive patients 
with AF initiated on anticoagulant therapy, which showed no 
significant difference in risk of transient ischaemic attack/isch-
aemic stroke/unspecified stroke/death (HR 0.97 (95% CI 0.87 to 
1.08)) or severe bleed (HR 1.02 95% CI 0.88 to 1.20)) between 
NOACs and VKA in patients with CHA2DS2- VASc score ≥2. This 
study also showed lower rates of overall mortality with NOAC 
than VKA, but this analysis was for the overall population (ie, 
not restricted to patients with CHA2DS2- VASc score ≥2).
23
Previous reports on the respective efficacy of NOAC versus 
VKA did not yield similar conclusions about risk of death, stroke/
SE or bleeding. A significant reduction in all- cause mortality with 
NOAC verus VKAs was observed in trials of apixaban and edox-
aban,5 6 but not with dabigatran or rivaroxaban, although the 
point estimates in all four trials were similar.4 7 In a meta- analysis 
of data from 71 638 participants in these pivotal phase III trials, 
RE- LY (dabigatran),4 ROCKET AF (rivaroxaban),7 ARISTOTLE 
(apixaban)6 and ENGAGE AF- TIMI 48 (edoxaban),5 NOACs 
reduced all- cause mortality (relative risk 0.90, 95% CI 0.85 to 
0.95) and stroke/SE events (relative risk 0.81, 95% CI 0.73 to 
0.91) in comparison with warfarin with a borderline difference 
in risk of major bleeding (relative risk vs warfarin 0.86, 95% 
CI 0.73 to 1.00).8 In a systematic review and meta- analysis 
including phase II and phase III RCTs comparing NOACs with 
warfarin in a total of 77 011 patients with AF, NOACs reduced 
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the risk of stroke/SE (OR 0.85, 95% CI 0.75 to 0.98), intracra-
nial haemorrhage (OR 0.48, 95% CI 0.40 to 0.57) and mortality 
(OR 0.86, 95% CI 0.82 to 0.91).24 Benefits over VKAs have 
also been demonstrated for the two NOAC subtypes, FXaIs and 
DTIs, in systematic reviews of RCTs.25 26 In a network meta- 
analysis of more than 90 000 patients, NOAC use compared 
with VKA was associated with reduced risks of both all- cause 
mortality and stroke/SE, with a similar risk of major bleeding.27
Strengths and limitations
As the largest multinational prospective registry in patients with AF, 
GARFIELD- AF captures the diversity of treatment and outcomes 
in populations beyond the constraints of RCTs, making it represen-
tative of the real- life management of AF worldwide. The registry 
uses regular audits, including a combination of remote and onsite 
monitoring to ascertain completeness and accuracy of all records. 
In addition, the country from which data were derived has a strong 
impact on the choice of therapy, particularly respective use OAC and 
of AP treatments that can influence the outcomes. The impact of 
these confounders on the observed differences in outcomes across 
the different treatments is difficult to assess. Applying appropriate 
statistical methods to balance these factors, such as used in this study, 
is of paramount importance. Dosing is not taken into account for this 
analyses, which may impact outcomes. Lastly, our analysis reflects 
the intention to treat over the duration of follow- up; treatments may 
have changed over time, and these changes would not be reflected 
in these analyses.
CONCLUSION
NOACs are recommended in international guidelines as broadly 
preferable to VKAs in the vast majority of patients with AF 
since the clinical trials have consistently shown non- inferiority 
in efficacy and better safety, with reduced risk of intracranial 
haemorrhage with NOACs.1 2 Our results, from the real world, 
strengthen this recommendation and demonstrate the benefits 
of NOACs in everyday clinical practice in patients with AF with 
CHA2DS2- VASc score ≥2 (excluding gender).
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Key messages
What is already known on this subject?
 ► Oral anticoagulation is recommended in patients with atrial 
fibrillation at moderate to high risk of stroke. Anticoagulants 
reduced ischaemic stroke risk in randomised controlled 
trials, but their use is associated with increased risk of 
bleeding, ranging from minor bleeding to fatal intracranial or 
extracranial haemorrhage.
What might this study add?
 ► In The Global Anticoagulant Registry in the FIELD–Atrial 
Fibrillation registry, among patients newly diagnosed with 
atrial fibrillation and a CHA2DS2- VASc score ≥2 (excluding 
gender) anticoagulated in everyday clinical practice, direct 
thrombin inhibitors and factor Xa inhibitors showed clear 
advantages in term of mortality reduction compared with 
vitamin K antagonists, with similar efficacy on stroke/systemic 
embolism, and reduced risk of major bleeding.
How might this impact on clinical practice?
 ► Our results, from the real world, strengthen the international 
guidelines recommendation and demonstrate the benefits 
of non- vitamin K antagonist oral anticoagulants in everyday 
clinical practice in patients with atrial fibrillation with 
CHA2DS2- VASc score ≥2 (excluding gender).
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Table S1. Distribution of patients by country with information on baseline OAC 
 
  
Country N Patients on OAC 
(row %) 
Japan 2836 80.9 
United Kingdom 2172 70.4 
Germany 1364 81.9 
Russia 1181 57.3 
Spain 1152 78.5 
Ukraine 1123 52.7 
China 1035 29.1 
Italy 1035 89.8 
Belgium 998 86.3 
Poland 986 84.6 
Czech Republic 941 78.0 
France 870 80.3 
Thailand 865 55.8 
South Korea 845 65.0 
Hungary 768 84.8 
India 739 35.1 
Chile 592 88.0 
Sweden 560 85.5 
Argentina 551 58.4 
United States 534 72.7 
Brazil 507 57.2 
Netherlands 481 95.0 
Mexico 454 62.3 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Heart
 doi: 10.1136/heartjnl-2020-318420–9.:10 2021;Heart, et al. Camm AJ
2 
Canada 408 67.9 
Egypt 367 89.7 
Turkey 363 69.2 
Australia 352 70.2 
South Africa 330 77.6 
United Arab Emirates 284 60.9 
Denmark 213 85.5 
Singapore 176 65.9 
Austria 164 79.9 
Finland 119 88.2 
Norway 114 88.6 
Switzerland 72 93.1 
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Table S2. Baseline characteristics by treatment at baseline 
Baseline characteristics Patients treated with OAC Patients not treated with 
OAC 
(N = 7162) 
FXaI 
(N = 7694) 
DTI 
(N = 2090) 
VKA 
(N = 8605) 
     
Body mass index, median (Q1; Q3), kg/m² 26.6 (23.7;30.4) 27.3 (24.4;31.6) 27.6 (24.4;31.6) 26.4 (23.5;30.1) 









Diastolic blood pressure, median (Q1; Q3), 
mmHg 
80.0 (70.0;88.0) 80.0 (70.0;90.0) 80.0 (70.0;90.0) 80.0 (70.0;88.0) 
Pulse, median (Q1; Q3), bpm 84.0 (70.0;106.0) 85.0 (70.0;110.0) 85.0 (72.0;104.0) 83.0 (70.0;105.0) 
Care setting specialty at diagnosis, n (%)     
Internal medicine/Neurology/Geriatrics 1483 (19.3) 339 (16.2) 1819 (21.1) 1493 (20.8) 
Cardiology 5387 (70.0) 1546 (74.0) 5227 (60.7) 4632 (64.7) 
Primary care/general practice 824 (10.7) 205 (9.8) 1559 (18.1) 1037 (14.5) 
Care setting location at diagnosis, n (%)     
Hospital 3610 (46.9) 1197 (57.3) 4880 (56.7) 4588 (64.1) 
Office/Anticoagulation clinic/Thrombosis 
centre 
3375 (43.9) 700 (33.5) 2711 (31.5) 1795 (25.1) 
Emergency room 709 (9.2) 193 (9.2) 1014 (11.8) 779 (10.9) 
Heavy alcohol consumption, n (%) 109 (1.7) 33 (1.9) 130 (1.8) 126 (2.1) 
Current smoker, n (%) 595 (8.5) 189 (9.8) 681 (8.6) 636 (9.7) 
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Table S3. Unadjusted and adjusted1 hazard ratios and corresponding 95% confidence intervals for selected outcomes at two years of follow-up by treatment 
at baseline 
Outcome Treatment comparison 
OAC vs No OAC (ref.)  NOAC vs VKA (ref.) 
Unadjusted  Adjusted1  Unadjusted  Adjusted1 
HR (95% CI) p-value  HR (95% CI) p-value HR (95% CI) p-value  HR (95% CI) p-value 
            
All-cause mortality 0.74 (0.68-0.81) <0.0001  0.82 (0.74-0.91) 0.0002  0.74 (0.67-0.82) <0.0001  0.79 (0.70-0.89) 0.0001 
            
Non-haemorrhagic 
stroke/SE 
0.67 (0.56-0.81) <0.0001  0.71 (0.57-0.88) 0.0021  0.82 (0.65-1.03) 0.0877  0.96 (0.73-1.25) 0.7360 
            
Major bleeding 1.51 (1.22-1.88) 0.0002  1.46 (1.15-1.86) 0.0022  0.70 (0.57-0.85) 0.0003  0.77 (0.61-0.98) 0.0363 
            
1Obtained using an overlap-weighted Cox model. Variables included in the weighting scheme are: country and cohort enrolment, sex, age, ethnicity, type of AF, care setting 
speciality and location, congestive heart failure, acute coronary syndromes, vascular disease, carotid occlusive disease, prior stroke/TIA/SE, prior bleeding, VTE, hypertension, 
hypercholesterolemia, diabetes, cirrhosis, moderate to severe CKD, dementia, hyperthyroidism, hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, 
systolic and diastolic blood pressure at diagnosis, and baseline antiplatelet use. 
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Table S4. Unadjusted and adjusted1 hazard ratios and corresponding 95% confidence intervals for selected outcomes at two years of follow-up 
by treatment at baseline 
Outcome Treatment comparison 
NOAC vs No OAC (ref.)  VKA vs No OAC (ref.) 
Unadjusted  Adjusted1  Unadjusted  Adjusted1 
HR (95% CI) p-value  HR (95% CI) p-value HR (95% CI) p-value  HR (95% CI) p-value 
            
All-cause mortality 0.64 (0.58-
0.71) 
<0.0001  0.67 (0.59-
0.77) 
<0.0001  0.86 (0.78-
0.95) 
0.0035  0.93 (0.82-
1.04) 
0.2088 





<0.0001  0.65 (0.50-
0.86) 
0.0020  0.75 (0.60-
0.93) 
0.0084  0.75 (0.58-
0.98) 
0.0315 
            
Major bleeding 1.26 (0.99-
1.61) 
0.0627  1.10 (0.82-
1.47) 
0.5239  1.80 (1.43-
2.28) 
<0.0001  1.86 (1.42-
2.44) 
<0.0001 
            
1Obtained using an overlap-weighted Cox model. Variables included in the weighting scheme are: country and cohort enrolment, sex, age, ethnicity, type of AF, care setting 
speciality and location, congestive heart failure, acute coronary syndromes, vascular disease, carotid occlusive disease, prior stroke/TIA/SE, prior bleeding, VTE, hypertension, 
hypercholesterolemia, diabetes, cirrhosis, moderate to severe CKD, dementia, hyperthyroidism, hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, 
systolic and diastolic blood pressure at diagnosis, and baseline antiplatelet use. 
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Table S5. Unadjusted and adjusted1 hazard ratios and corresponding 95% confidence intervals for selected outcomes at two years of follow-up 





HR (95% CI) 
Adjusted1 
HR (95% CI) 
Baseline treatment   
All-cause mortality   
DTI vs VKA 0.68 (0.57-0.82) 0.83 (0.71-0.98) 
FXaI vs VKA 0.76 (0.68-0.85) 0.77 (0.65-0.92) 
FXaI vs DTI 1.11 (0.92-1.35) 0.92 (0.80-1.06) 
Non-haemorrhagic stroke/SE   
DTI vs VKA 0.90 (0.62-1.30) 1.01 (0.74-1.39) 
FXaI vs VKA 0.80 (0.63-1.02) 0.92 (0.67-1.27) 
FXaI vs DTI 0.89 (0.61-1.31) 0.91 (0.58-1.44) 
Major bleeding   
DTI vs VKA 0.53 (0.36-0.77) 0.68 (0.47-0.98) 
FXaI vs VKA 0.75 (0.61-0.92) 0.84 (0.63-1.12) 
FXaI vs DTI 1.42 (0.95-2.11) 1.24 (0.90-1.73) 
1Obtained using an overlap-weighted Cox model. Variables included in the weighting scheme are: country and cohort enrolment, sex, age, ethnicity, type of AF, care setting 
speciality and location, congestive heart failure, acute coronary syndromes, vascular disease, carotid occlusive disease, prior stroke/TIA/SE, prior bleeding, VTE, hypertension, 
hypercholesterolemia, diabetes, cirrhosis, moderate to severe CKD, dementia, hyperthyroidism, hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, 
systolic and diastolic blood pressure at diagnosis, and baseline antiplatelet use. 
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Figure S5. Flowchart for the selection of the study population 
 
GARFIELD-AF cohorts 3 to 5
(N = 34,926)
Males with CHA₂DS₂-VASc
score ≥2, females with ≥3
(N = 27,208)
Patients not treated with VKA 
before enrolment
(N = 25,874)
Excluded: Patients with CHA₂DS₂-
VASc score <2 or missing
(N = 7718)
Excluded: Patients treated with 
VKA before enrolment
(N = 1334)
Patients treated with OAC
(N =18,389; 72.0%)
Patients not treated with OAC
(N = 7162; 28.0%)
Patients treated with 
FXaI
(N = 7694; 41.8%)
Patients treated with 
VKA
(N = 8605; 46.8%)
Excluded: Patients with missing 
treatment information
(N = 304)
Patients with available 
treatment information
(N = 25,570)
Patients with available follow-
up information
(N = 25,551)
Excluded: Patients with missing 
follow-up information
(N = 19)
Patients treated with 
DTI
(N = 2090; 11.4%)
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Figure S6. Adjusted1 hazard ratios and corresponding 95% confidence intervals for selected outcomes at 2 years of follow-up by OAC treatment 




1Obtained using an overlap-weighted Cox model. Variables included in the weighting scheme are: 
country and cohort enrolment, sex, age, ethnicity, type of AF, care setting speciality and location, congestive heart failure, acute coronary syndromes, 
vascular disease, carotid occlusive disease, prior stroke/TIA/SE, prior bleeding, VTE, hypertension, hypercholesterolemia, diabetes, cirrhosis, moderate to 
severe CKD, dementia, hyperthyroidism, hypothyroidism, current smoking, heavy alcohol consumption, BMI, heart rate, systolic and diastolic blood pressure 
at diagnosis, and baseline antiplatelet use. 
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